4 citations
,
September 2019 in “Biomedical Papers/Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc Czech Republic” This study found that CD2 could be a potential new therapeutic target for treating patchy-type alopecia areata, suggesting the need for further research into its role.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.
August 2026 in “Journal of Cosmetic Dermatology” This study found that platelet-rich plasma showed similar efficacy to intralesional triamcinolone acetonide for treating mild patch-type alopecia areata, offering a potential alternative with fewer steroid-related side effects.
May 2024 in “Journal of Pakistan Association of Dermatologists” This study observed no statistically significant relationship between vitamin D levels and alopecia areata, including different types of the disease, suggesting vitamin D may not play a central role in its development or extent among a sample of adults.
July 2024 in “Journal of Investigative Dermatology” JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.